Additionally, patients testing positive only for aCL and/or aβ2GP1 IgM, regardless of the titer, will not meet the new criteria for APS despite the fact that those with double positivity for aCL and aβ2GP1 IgM are recognized to have a high-risk thrombotic profile [85]. This evidence concerns the gene CD40LG and autoimmune polyendocrinopathy.